In vivo knockdown of CXCR4 using jetPEI/CXCR4 shRNA nanoparticles inhibits the pulmonary metastatic potential of B16‑F10 melanoma cells

André,Nayara Delgado; Silva,Viviane   Aline Oliveira; Ariza,Carolina  Batista; Watanabe,Maria Angelica Ehara; De Lucca,Fernando Luiz

doi:10.3892/mmr.2015.4487

In vivo knockdown of CXCR4 using jetPEI/CXCR4 shRNA nanoparticles inhibits the pulmonary metastatic potential of B16‑F10 melanoma cells

Authors:
- Nayara Delgado André
- Viviane Aline Oliveira Silva
- Carolina Batista Ariza
- Maria Angelica Ehara Watanabe
- Fernando Luiz De Lucca
View Affiliations

Affiliations: Federal University of São João del‑Rei, Divinópolis, Minas Gerais 35501‑296, Brazil, Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14049‑900, Brazil, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Londrina, Paraná 86057‑970, Brazil
Published online on: October 26, 2015 https://doi.org/10.3892/mmr.2015.4487
Pages: 8320-8326

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis is a key factor that limits survival in the majority of patients with cancer. Thus, numerous efforts have been made to elucidate the molecular mechanisms involved in this phenomenon. B16‑F10 melanoma cells have been demonstrated to be highly metastatic to the lungs in mice. The aim of the current study was to investigate the role of CXC motif chemokine receptor 4 (CXCR4) in the metastatic potential of B16‑F10 melanoma cells in mice. In vitro transfection of B16‑F10 tumor cells with CXCR4 short hairpin RNA (shRNA) expressing plasmids (CXCR4 shRNA) significantly reduced the expression levels of CXCR4 mRNA (80%) and protein (68%), compared with the control. In addition, these results demonstrated that pulmonary metastasis was significantly inhibited (85%) in mice inoculated with CXCR4 shRNA‑transfected B16‑F10 melanoma cells. The polycation‑based nanoparticle (jetPEI) was used to investigate the effect of CXCR4 knockdown in vivo on the metastatic potential of B16‑F10 melanoma cells. The number of pulmonary metastatic nodules was significantly reduced (50%) in animals that received a retro‑orbital injection of jetPEI‑CXCR4‑1 shRNA. The current study demonstrated that CXCR4 serves a role in the metastatic potential of B16‑F10 melanoma cells. Currently there is a great interest in the development of antagonists for the therapeutic targeting of CXCR4 expression. Taking the results of the current study and the fact that CXCR4 is highly conserved between humans and mice into account, this experimental model of metastasis with B16‑F10 melanoma cells may aid in the discovery of CXCR4 antagonists with clinical implications.

View Figures

View References

1	Scala S, Giuliano P, Ascierto PA, Ieranò C, Franco R, Napolitano M, Ottaiano A, Lombardi ML, Luongo M, Simeone E, et al: Human melanoma metastases express functional CXCR4. Clin Cancer Res. 12:2427–2433. 2006. View Article : Google Scholar : PubMed/NCBI
2	Tsao H, Atkins MB and Sober AJ: Management of cutaneous melanoma. N Engl J Med. 351:998–1012. 2004. View Article : Google Scholar : PubMed/NCBI
3	Chatterjee S, Behnam Azad B and Nimmagadda S: The intricate role of CXCR4 in cancer. Adv Cancer Res. 124:31–82. 2014. View Article : Google Scholar : PubMed/NCBI
4	Zlotnik A: Chemokines in neoplastic progression. Semin Cancer Biol. 14:181–185. 2004. View Article : Google Scholar : PubMed/NCBI
5	Zlotnik A, Burkhardt AM and Homey B: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 11:597–606. 2011. View Article : Google Scholar : PubMed/NCBI
6	Murdoch C: CXCR4: Chemokine receptor extraordinaire. Immunol Rev. 177:175–184. 2000. View Article : Google Scholar
7	Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:50–56. 2001. View Article : Google Scholar : PubMed/NCBI
8	Toyozawa S, Kaminaka C, Furukawa F, Nakamura Y, Matsunaka H and Yamamoto Y: Chemokine receptor CXCR4 is a novel marker for the progression of cutaneous malignant melanomas. Acta Histochem Cytochem. 45:293–299. 2012. View Article : Google Scholar : PubMed/NCBI
9	Mitchell B, Leone D, Feller JK, Bondzie P, Yang S, Park HY and Mahalingam M: Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status. Melanoma Res. 24:621–625. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zhou J, Liu R, Wang Y, Tang J, Tang S, Chen X, Xia K, Xiong W, Xu D, Wang S, et al: miR-199a-5p regulates the expression of metastasis associated genes in B16-F10 melanoma cells. Int J Clin Exp Pathol. 7:7182–7190. 2014.
11	Burger JA and Kipps TJ: CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 107:1761–1767. 2006. View Article : Google Scholar
12	Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D and Jain RK: CXCL12 (SDF1-α) - CXCR4/CXCR7 pathway inhi bition: An emerging sensitizer for anticancer therapies. Clin Cancer Res. 17:2074–2080. 2011. View Article : Google Scholar : PubMed/NCBI
13	Li Z, Li N, Wu M, Li X, Luo Z and Wang X: Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4. Mol Cell Biochem. 381:233–242. 2013. View Article : Google Scholar : PubMed/NCBI
14	Fidler IJ: Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35:218–224. 1975.PubMed/NCBI
15	Bobek V, Kolostova K, Pinterova D, Kacprzak G, Adamiak J, Kolodziej J, Boubelik M, Kubecova M and Hoffman RM: A clinically relevant, syngeneic model of spontaneous, highly metastatic B16 mouse melanoma. Anticancer Res. 30:4799–4803. 2010.PubMed/NCBI
16	Chung TW, Choi HJ, Lee JY, Jeong HS, Kim CH, Joo M, Choi JY, Han CW, Kim SY, Choi JS and Ha KT: Marine algal fucoxanthin inhibits the metastatic potential of cancer cells. Biochem Biophys Res Commun. 439:580–585. 2013. View Article : Google Scholar : PubMed/NCBI
17	Novina CD and Sharp PA: The RNAi revolution. Nature. 430:161–164. 2004. View Article : Google Scholar : PubMed/NCBI
18	Masiero M, Nardo G, Indraccolo S and Favaro E: RNA interference: implications for cancer treatment. Mol Aspects Med. 28:143–166. 2007. View Article : Google Scholar : PubMed/NCBI
19	Mansoori B, Sandoghchian Shotorbani S and Baradaran B: RNA interference and its role in cancer therapy. Adv Pharm Bull. 4:313–321. 2014.PubMed/NCBI
20	Delgado André N and De Lucca FL: Knockdown of PKR expression by RNAi reduces pulmonary metastatic potential of B16-F10 melanoma cells in mice: Possible role of NF-kappaB. Cancer Lett. 258:118–125. 2007. View Article : Google Scholar : PubMed/NCBI
21	André ND, Silva VA, Watanabe MA and De Lucca FL: Intratumoral injection of PKR shRNA expressing plasmid inhibits B16-F10 melanoma growth. Oncol Rep. 32:2267–2273. 2014.PubMed/NCBI
22	Cadman E, Bostwick JR and Eichberg J: Determination of protein by a modified Lowry procedure in the presence of some commonly used detergents. Anal Biochem. 96(1): 21–23. 1979. View Article : Google Scholar : PubMed/NCBI
23	Yardeni T, Eckhaus M, Morris HD, Huizing M and Hoogstraten-Miller S: Retro orbital injections in mice. Lab Anim. 40:155–160. 2011. View Article : Google Scholar
24	Howard KA and Kjems J: Polycation-based nanoparticle delivery for improved RNA interference therapeutics. Expert Opin Biol Ther. 7:1811–1822. 2007. View Article : Google Scholar : PubMed/NCBI
25	Aigner A: Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol. 76:9–21. 2007. View Article : Google Scholar : PubMed/NCBI
26	Gao S, Dagnaes-Hansen F, Nielsen EJ, Wengel J, Besenbacher F, Howard KA and Kjems J: The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther. 17:1225–1233. 2009. View Article : Google Scholar : PubMed/NCBI
27	Heesen M, Berman MA, Benson JD, Gerard C and Dorf ME: Cloning of the mouse fusin gene, homologue to a human HIV-1 co-factor. J Immunol. 157:5455–5460. 1996.PubMed/NCBI